Adverse drug reactions induced by cardiovascular drugs in cardiovascular care unit patients

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 9, 2010, Pages 889-894

  Mohebbi, Niayesh ^a   Shalviri, Gloria ^b   Salarifar, Mojtaba ^c   Salamzadeh, Jamshid ^d   Gholami, Kheirollah ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adverse drug reaction; Cardiovascular drugs; CCU patients

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ATENOLOL; CAPTOPRIL; CARDIOVASCULAR AGENT; CARVEDILOL; DIGOXIN; DILTIAZEM; DOBUTAMINE; DOPAMINE; ENOXACIN; FUROSEMIDE; GLYCERYL TRINITRATE; HEPARIN; ISOSORBIDE; LOSARTAN; METOPROLOL; MEVINOLIN; MEXILETINE; PENTOXIFYLLINE; PRAZOSIN; PROPRANOLOL; SPIRONOLACTONE; STREPTOKINASE; WARFARIN;

ADULT; APNEA; APPLICATION SITE REACTION; ARTICLE; BILIARY TRACT DISEASE; BILIRUBIN BLOOD LEVEL; BLEEDING DISORDER; BLOOD CLOTTING DISORDER; BODY WEIGHT; BRADYCARDIA; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CREATININE BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFECT; DRUG WITHDRAWAL; ERYTHROCYTE DISORDER; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HEART BLOCK; HEART VENTRICLE EXTRASYSTOLE; HEMATEMESIS; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NUTRITIONAL DISORDER; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL NEUROPATHY; PHYSICAL DISEASE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; RISK FACTOR; SENSORY DYSFUNCTION; SIDE EFFECT; SKIN APPENDAGE DISEASE; SKIN DISEASE; SMOKING; THROMBOCYTE DYSFUNCTION; UNSPECIFIED SIDE EFFECT; URINARY TRACT DISEASE; VASCULAR DISEASE;

AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CORONARY CARE UNITS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; IRAN; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RISK FACTORS; SMOKING; YOUNG ADULT;

EID: 77957351456     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1916     Document Type: Article

References (20)

1. Gholami K, Ziaie S, Shalviri G. Adverse drug reactions induced by cardiovascular drugs in outpatients. Pharm Pract 2008; 6: 51-55.
2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-1205.
3. Bates DW, Spell N, Cullen DI, et al. The cost of adverse drug events in hospitalized patients. Adverse drug events prevention study group. JAMA 1997; 277: 307-311.
4. Classen C, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997; 277: 301-306.
5. Levy M, Kewitz M, Altwein W, et al. Hospital admissions due to adverse drug reactions: a comparative study from Jerusalem and Berlin. Eur J Clin Pharmacol 1980; 17: 25-31.
6. Fanikos J, Cina JL, Baroletti S, et al. Adverse drug events in hospitalized cardiac patients. Am J Cardio 2007; 100: 1465-1469.
7. Zaidestein R, Eyal S, Efrati S, et al. Adverse drug events in hospitalized patients treated with cardiovascular drugs and anticoagulants. Pharmacoepidemiol Drug Saf 2002; 11: 235-238.
8. Frishman WH, Brosnan BD, Grossman M, et al. Adverse dermatologic effects of cardiovascular drug therapy: part 111. Cardiol Rev 2002; 10(6): 337-348. (Pubitemid 35266255)
9. Kanjanarat P, Winterstein AG, Johns TE, et al. Nature of preventable adverse drug events in hospitals: a literature review. Am J Health - Syst Pharm 2003; 60: 1750-1759.
10. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med 2004; 140: 795-801.
11. World Health Organization. Safety monitory of medical products, guidelines for setting up and running a pharmacovigilance centre 2000.
12. Schumock GT, Thornton JP. Focusing on preventability of adverse drug reactions. Hosp Pharm 1992; 27: 538.
13. Davidson F, Haghfelt T, Gram LF, et al. Adverse drug reactions and drug non - compliance as primary cause of admission to a cardiology department. Eur J Clin Pharmacol 1988; 34: 83-86.
14. Onder G, Pedone C, Landi F, et al. Adverse drug reactions as cause of hospital admissions: result from the Italian group of pharmacoepidemiology in elderly. J Am Geriatr Soc 2002; 50: 1962-1968.
15. Pouyanne P, Haramburu F, Imbs JL, et al. Admission to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres. Br Med J 2000; 320: 1036.
16. Fattinger K, Roos M, Vergeres P, et al. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol 2000; 49: 158-167.
17. Wiffen P, Gill M, Edwards J, Moore A. Adverse drug reactions in hospital patients. Bandolier Extra 2002; 1-15. http://www.bandolier.com.
18. Classen C, Pestotnik SL, Evans RS, et al. Computerized surveillance adverse drug events in hospital patients. Qual Saf Health Care 2005; 14: 221-226.
19. Bongard V, Mar CD, Philippe V, et al. Incidence rate of adverse drug reactions during long-term fallow-up of patients newly treated with amiodarone. Am J Ther 2006; 13: 315-319.
20. Mjorndal T, Boman MD, Hgg S, et al. Adverse drug reactions as a cause of admissions to a department of internal medicine. Pharmacoepidemoiol Drug Saf 2002; 11: 65-72.